Industry News (Joint Venture)

Worldwide License Agreement Signed for Phase III Cancer Drug

Published in Cancer Weekly, December 8th, 1997

Boehringer Ingelheim GmbH, Ingelheim, Germany, and Vion Pharmaceuticals, Inc., New Haven, Connecticut, jointly announced that the two companies have entered into an exclusive worldwide licensing agreement for the development and marketing of Promycin (porfiromycin), Vion's lead anti-cancer agent.

Promycin, a bioreductive alkylating agent, currently is being investigated in Phase III clinical trials for use in combination with radiation therapy for solid tumors of the head and neck.

Promycin is a therapeutic for hypoxic (oxygen-depleted) cancer cells, which are known to be less susceptible to radiation therapy than other tumor cells. Promycin was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-12-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry